These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 37957455)

  • 21. Retrospective analysis of
    Guo Y; Guo N; Wang J; Wang R; Tang L
    Ren Fail; 2021 Dec; 43(1):729-736. PubMed ID: 33904354
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical Predictors of Response to Prednisone Plus Cyclophosphamide in Patients with Idiopathic Membranous Nephropathy.
    Li S; Wang L; Zhang M; Zhou W; Fang W; Wang Q; Qi C; Mou S; Shao X; Ni Z
    Nephron; 2017; 135(2):87-96. PubMed ID: 27974710
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rituximab or Cyclophosphamide in the Treatment of Membranous Nephropathy: The RI-CYCLO Randomized Trial.
    Scolari F; Delbarba E; Santoro D; Gesualdo L; Pani A; Dallera N; Mani LY; Santostefano M; Feriozzi S; Quaglia M; Boscutti G; Ferrantelli A; Marcantoni C; Passerini P; Magistroni R; Alberici F; Ghiggeri GM; Ponticelli C; Ravani P;
    J Am Soc Nephrol; 2021 Apr; 32(4):972-982. PubMed ID: 33649098
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rituximab for the management of idiopathic membranous nephropathy: a meta-analysis.
    Huang L; Dong QR; Zhao YJ; Hu GC
    Int Urol Nephrol; 2021 Jan; 53(1):111-119. PubMed ID: 32944889
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinicopathological features and outcome in elderly patients with idiopathic membranous nephropathy.
    Liang J; Hao W; Xia F; Zhao Z; Wu Y; Yu F; Hu W; Fang X; Liu W
    Ren Fail; 2023 Dec; 45(1):2212081. PubMed ID: 37194712
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rituximab for Severe Membranous Nephropathy: A 6-Month Trial with Extended Follow-Up.
    Dahan K; Debiec H; Plaisier E; Cachanado M; Rousseau A; Wakselman L; Michel PA; Mihout F; Dussol B; Matignon M; Mousson C; Simon T; Ronco P;
    J Am Soc Nephrol; 2017 Jan; 28(1):348-358. PubMed ID: 27352623
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rituximab for the treatment of membranous nephropathy: a single-center experience.
    Aleš Rigler A; Jerman A; Orsag A; Kojc N; Kovač D; Škoberne A; Borštnar Š; Večerić Haler Ž; Avguštin N; Kveder R; Ferluga D; Vizjak A; Lindič J
    Clin Nephrol; 2017 Supplement 1; 88(13):27-31. PubMed ID: 28664837
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Profile and primary treatment outcomes in membranous nephropathy.
    Hemanth Kumar MK; Sandhu J; Sandhu JS
    Saudi Med J; 2022 Sep; 43(9):1051-1056. PubMed ID: 36104046
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Leflunomide plus oral prednisone in treatment of idiopathic membranous nephropathy: a retrospective clinical study of efficacy and safety.
    Yang S; Xie L; Xue W; Yin A; Lu W
    Nephrology (Carlton); 2013 Sep; 18(9):615-22. PubMed ID: 23889815
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Beneficial effect of rituximab in the treatment of recurrent idiopathic membranous nephropathy after kidney transplantation.
    Sprangers B; Lefkowitz GI; Cohen SD; Stokes MB; Valeri A; Appel GB; Kunis CL
    Clin J Am Soc Nephrol; 2010 May; 5(5):790-7. PubMed ID: 20185599
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term outcomes of persistent disease and relapse in primary membranous nephropathy.
    Kanigicherla DA; Short CD; Roberts SA; Hamilton P; Nikam M; Harris S; Brenchley PE; Venning MC
    Nephrol Dial Transplant; 2016 Dec; 31(12):2108-2114. PubMed ID: 26769682
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predictors of response and relapse in patients with idiopathic membranous nephropathy treated with tacrolimus.
    Caro J; Gutiérrez-Solís E; Rojas-Rivera J; Agraz I; Ramos N; Rabasco C; Espinosa M; Valera A; Martín M; Frutos MÁ; Perea L; Juárez GF; Ocaña J; Arroyo D; Goicoechea M; Fernández L; Oliet A; Hernández Y; Romera A; Segarra A; Praga M;
    Nephrol Dial Transplant; 2015 Mar; 30(3):467-74. PubMed ID: 25274748
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rituximab for non-responsive idiopathic membranous nephropathy in a Chinese cohort.
    Wang X; Cui Z; Zhang YM; Qu Z; Wang F; Meng LQ; Cheng XY; Liu G; Zhou FD; Zhao MH
    Nephrol Dial Transplant; 2018 Sep; 33(9):1558-1563. PubMed ID: 29149305
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Urinary protein and renal prognosis in idiopathic membranous nephropathy: a multicenter retrospective cohort study in Japan.
    Yamaguchi M; Ando M; Katsuno T; Tsuboi N; Maruyama S
    Ren Fail; 2018 Nov; 40(1):435-441. PubMed ID: 30052488
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Out of Africa: Complete and partial remissions as a combined outcome in patients with idiopathic membranous glomerulonephritis in Cape Town.
    Ameh OI; Swanepoel CR; Aderibigbe A; Kengne AP; Okpechi IG
    Nephrology (Carlton); 2016 Dec; 21(12):1010-1016. PubMed ID: 26706191
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intravenous pulse cyclophosphamide and steroids induce immunological and clinical remission in New-incident and relapsing primary membranous nephropathy.
    Kanigicherla DAK; Hamilton P; Czapla K; Brenchley PE
    Nephrology (Carlton); 2018 Jan; 23(1):60-68. PubMed ID: 27778424
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Long-term efficacy of low-dose rituximab treatment in patients with primary membranous nephropathy].
    Qi Y; Jia JY; Gu QH; Zheng ZF; Li LN; Li D; Jia ZH; Xue Y; Yan TK
    Zhonghua Yi Xue Za Zhi; 2022 Nov; 102(40):3201-3206. PubMed ID: 36319174
    [No Abstract]   [Full Text] [Related]  

  • 38. Synthetic ACTH in High Risk Patients with Idiopathic Membranous Nephropathy: A Prospective, Open Label Cohort Study.
    van de Logt AE; Beerenhout CH; Brink HS; van de Kerkhof JJ; Wetzels JF; Hofstra JM
    PLoS One; 2015; 10(11):e0142033. PubMed ID: 26562836
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Our experience with rituximab therapy for adult-onset primary glomerulonephritis and review of literature.
    Kong WY; Swaminathan R; Irish A
    Int Urol Nephrol; 2013 Jun; 45(3):795-802. PubMed ID: 22798030
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Outcome of idiopathic membranous nephropathy using targeted stepwise immunosuppressive treatment strategy.
    Aaltonen S; Honkanen E
    Nephrol Dial Transplant; 2011 Sep; 26(9):2871-7. PubMed ID: 21427071
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.